Optimizing Darbepoetin Use to Reduce Blood Transfusions in Premature Infants: Key Findings from Recent Study

A recent groundbreaking study published in the Journal of Perinatology explores how to effectively minimize blood transfusions in premature newborns through the precise administration of Darbepoetin (Darbe). This research stems from a collaborative effort between neonatologists at Intermountain Healthcare in Salt Lake City and clinical experts from the University of Utah.

Premature infants commonly experience anemia, characterized by low red blood cell counts, which can lead to developmental delays and respiratory issues. For over two decades, subcutaneous Darbe injections have been a key treatment for anemia of prematurity, promoting red blood cell production and thereby reducing the need for transfusions.

The study aimed to refine the dosage and dosing intervals of Darbe to optimize treatment outcomes while limiting the number of injections. Researchers tested two dosing schedules: weekly injections and injections every two weeks. Conducted at Intermountain Medical Center in Murray and Utah Valley Hospital in Provo, the trial produced promising results.

Dr. Timothy Bahr, a neonatologist involved in the research, highlighted that although weekly dosing led to a slight increase in red blood cell production, both schedules resulted in comparable overall health outcomes. He emphasized that administering Darbe every two weeks could serve as a viable alternative, reducing the injection frequency.

Fewer injections not only improve comfort for preemies and their families but also potentially reduce healthcare costs. Importantly, increasing red blood cell counts with Darbe diminishes the necessity for blood transfusions, which, while often lifesaving, carry risks of complications.

Dr. Bahr noted that the transfusion rates at Intermountain’s neonatal ICUs are notably below the national average, partly due to the responsible use of Darbe and ongoing research efforts.

This approach aligns with Intermountain’s broader initiative to promote "transfusion stewardship," paralleling antibiotic stewardship programs aimed at responsible medication use. Elizabeth O’Brien, MD, added that this new dosing strategy offers a balanced solution, combining effective treatment with fewer medical interventions, thereby enhancing patient care.

Intermountain’s comprehensive neonatal facilities, including the leading Level IV Neonatal ICU in the Mountain West, support the implementation of these findings across their hospitals. With continuous access to neonatal telemedicine, providers are equipped to deliver advanced, compassionate care to premature infants across rural and urban settings.

This study signifies a meaningful step toward safer, more effective management of anemia in preemies and underscores Intermountain’s commitment to innovation in neonatal health.